Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating
clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An …

Therapies with novel mechanisms of action are needed for multiple myeloma (MM). B-cell
maturation antigen (BCMA) is expressed in most cases of MM. We conducted the first-in …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Background The phase 3 ENDEAVOR trial was a head-to-head comparison of two
proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression …

Extramedullary myeloma (EMM) is defined by the presence of plasma cells (PCs) outside
the bone marrow in a patient with multiple myeloma (MM). Using sensitive imaging …

Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …

Proteasome inhibitor (PI) carfilzomib (CFZ) has activity superior to bortezomib (BTZ) and is
increasingly incorporated in multiple myeloma (MM) frontline therapy and relapsed settings …

Summary Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO 1,
also termed CRM 1). Non‐clinical studies support combining selinexor with proteasome …

Multiple myeloma (MM), one of the most prevalent hematological malignancies, accounts for
approximately 10% of all blood cancers. In spite of the recent advancements in MM therapy …